NYSE:MRK - Merck & Co., Inc. Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$82.29 -0.66 (-0.80 %)
(As of 03/22/2019 04:00 PM ET)
Previous Close$82.29
Today's Range$82.0164 - $83.45
52-Week Range$52.83 - $83.45
Volume10.15 million shs
Average Volume9.70 million shs
Market Capitalization$221.87 billion
P/E Ratio18.96
Dividend Yield2.65%
Beta0.62
Merck & Co., Inc. provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases. It also provides neuromuscular blocking agents; cholesterol modifying medicines; and anti-bacterial and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors, and metastatic non-small-cell lung cancer; prevent diseases caused by human papillomavirus; and vaccines for measles, mumps, rubella, varicella, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. The company also provides companion animal products, such as ointments; diabetes mellitus; anthelmintic products; fluralaner products to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It has collaborations with Pfizer Inc.; AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; IO Biotech; Premier Inc.; Cue Biopharma, Inc.; Foundation Medicine, Inc.; Daiichi Sankyo Company, Limited; Cold Genesys, Inc.; Kyn Therapeutics; Adlai Nortye Ltd.; Cocrystal Pharma, Inc.; and Instituto Butantan. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, distributors, veterinarians, animal producers, and managed health care providers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Receive MRK News and Ratings via Email

Sign-up to receive the latest news and ratings for MRK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP58933Y10
Phone908-740-4000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$42.29 billion
Cash Flow$5.9372 per share
Book Value$9.97 per share

Profitability

Net Income$6.22 billion

Miscellaneous

Employees69,000
Outstanding Shares2,696,190,000
Market Cap$221.87 billion
Next Earnings Date5/7/2019 (Estimated)
OptionableOptionable

Merck & Co., Inc. (NYSE:MRK) Frequently Asked Questions

What is Merck & Co., Inc.'s stock symbol?

Merck & Co., Inc. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

How often does Merck & Co., Inc. pay dividends? What is the dividend yield for Merck & Co., Inc.?

Merck & Co., Inc. announced a quarterly dividend on Tuesday, January 29th. Shareholders of record on Friday, March 15th will be given a dividend of $0.55 per share on Friday, April 5th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 2.67%. The ex-dividend date is Thursday, March 14th. View Merck & Co., Inc.'s Dividend History.

How will Merck & Co., Inc.'s stock buyback program work?

Merck & Co., Inc. announced that its Board of Directors has approved a share repurchase plan on Thursday, October 25th 2018, which permits the company to buyback $10,000,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to purchase up to 5.1% of its shares through open market purchases. Shares buyback plans are generally an indication that the company's board of directors believes its shares are undervalued.

How were Merck & Co., Inc.'s earnings last quarter?

Merck & Co., Inc. (NYSE:MRK) announced its earnings results on Friday, February, 1st. The company reported $1.04 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $1.03 by $0.01. The company earned $11 billion during the quarter, compared to analysts' expectations of $10.93 billion. Merck & Co., Inc. had a net margin of 14.71% and a return on equity of 36.83%. The business's quarterly revenue was up 5.4% compared to the same quarter last year. During the same period in the prior year, the company earned $0.98 earnings per share. View Merck & Co., Inc.'s Earnings History.

When is Merck & Co., Inc.'s next earnings date?

Merck & Co., Inc. is scheduled to release their next quarterly earnings announcement on Tuesday, May 7th 2019. View Earnings Estimates for Merck & Co., Inc..

What guidance has Merck & Co., Inc. issued on next quarter's earnings?

Merck & Co., Inc. updated its FY19 earnings guidance on Friday, February, 1st. The company provided earnings per share (EPS) guidance of $4.57-4.72 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.70. The company issued revenue guidance of $43.2-44.7 billion, compared to the consensus revenue estimate of $44.42 billion.Merck & Co., Inc. also updated its FY 2019 guidance to $4.57-4.72 EPS.

What price target have analysts set for MRK?

15 Wall Street analysts have issued twelve-month target prices for Merck & Co., Inc.'s stock. Their predictions range from $58.83 to $95.00. On average, they expect Merck & Co., Inc.'s stock price to reach $76.5692 in the next twelve months. This suggests that the stock has a possible downside of 7.0%. View Analyst Price Targets for Merck & Co., Inc..

What is the consensus analysts' recommendation for Merck & Co., Inc.?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merck & Co., Inc. in the last year. There are currently 5 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Merck & Co., Inc..

What are Wall Street analysts saying about Merck & Co., Inc. stock?

Here are some recent quotes from research analysts about Merck & Co., Inc. stock:
  • 1. Cantor Fitzgerald analysts commented, "We rate MRK 12-month PT of $95. We think there is upside to Keytruda sales estimates. Sales growth across oncology, vaccines, animal health, and select hospital/specialty care products, as well as margin expansion opportunities, are underappreciated, in our view. Therefore, we expect upward earnings revisions and multiple expansion in 2019+ to drive MRK’s shares higher. Valuation Summary We arrive at our 12-month price target of $95 for Merck shares by using a blend of Base case analyses." (3/4/2019)
  • 2. According to Zacks Investment Research, "Merck’s new products like Keytruda, Lynparza, and Bridion are contributing meaningfully to the top line. Keytruda sales are gaining momentum with approval for additional indications, especially in the first-line lung cancer setting as it is the only anti-PD-1 approved in this setting. Animal health and vaccine products are also performing strongly and remain core growth drivers for Merck. Meanwhile, Merck will continue to focus on cost-cutting initiatives to drive the bottom line. However, generic competition for several drugs and pricing pressure will continue to be overhangs on the top line. Rising competitive pressure on the diabetes franchise and on products like Isentress (HIV), Zepatier (HCV) and Zostavax (vaccine) remains. Merck’s shares have outperformed the industry in the past one year. Estimates have gone down slightly ahead of Q4 results. Merck has a positive record of earnings surprises in the recent quarters." (1/24/2019)

Has Merck & Co., Inc. been receiving favorable news coverage?

Media headlines about MRK stock have been trending neutral recently, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Merck & Co., Inc. earned a media sentiment score of 0.2 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term.

Are investors shorting Merck & Co., Inc.?

Merck & Co., Inc. saw a increase in short interest during the month of February. As of February 15th, there was short interest totalling 40,587,926 shares, an increase of 17.5% from the January 31st total of 34,557,279 shares. Based on an average daily trading volume, of 10,925,513 shares, the days-to-cover ratio is presently 3.7 days. Approximately 1.6% of the company's shares are sold short. View Merck & Co., Inc.'s Current Options Chain.

Who are some of Merck & Co., Inc.'s key competitors?

What other stocks do shareholders of Merck & Co., Inc. own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Merck & Co., Inc. investors own include Pfizer (PFE), Intel (INTC), AT&T (T), Johnson & Johnson (JNJ), Cisco Systems (CSCO), General Electric (GE), Verizon Communications (VZ), JPMorgan Chase & Co. (JPM), Bank of America (BAC) and Exxon Mobil (XOM).

Who are Merck & Co., Inc.'s key executives?

Merck & Co., Inc.'s management team includes the folowing people:
  • Mr. Kenneth C. Frazier, Chairman, CEO & Pres (Age 64)
  • Mr. Robert M. Davis, CFO & Exec. VP of Global Services (Age 52)
  • Dr. Roger M. Perlmutter, Exec. VP & Pres of Merck Research Laboratories (Age 67)
  • Mr. Adam H. Schechter, Special Advisor (Age 54)
  • Ms. Rita A. Karachun, Principal Accounting Officer, Sr. VP of Fin. & Global Controller (Age 55)

Who are Merck & Co., Inc.'s major shareholders?

Merck & Co., Inc.'s stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.22%), Oregon Public Employees Retirement Fund (1.97%), Bank of New York Mellon Corp (1.41%), Geode Capital Management LLC (1.26%), Northern Trust Corp (1.21%) and Norges Bank (1.05%). Company insiders that own Merck & Co., Inc. stock include Adam H Schechter, Ashley Watson, C Robert Kidder, Julie L Gerberding, Kenneth C Frazier, Leslie A Brun, Merck & Co, Inc, Michael J Holston, Richard R Deluca, Rita A Karachun, Roger M Perlmutter, Sanat Chattopadhyay, Thomas H Glocer, Weir Mirian M Graddick and Wendell P Weeks. View Institutional Ownership Trends for Merck & Co., Inc..

Which major investors are selling Merck & Co., Inc. stock?

MRK stock was sold by a variety of institutional investors in the last quarter, including Boston Partners, American International Group Inc., Barrow Hanley Mewhinney & Strauss LLC, Levin Capital Strategies L.P., Nomura Holdings Inc., Third Point LLC, Polar Capital LLP and Canada Pension Plan Investment Board. Company insiders that have sold Merck & Co., Inc. company stock in the last year include Adam H Schechter, Ashley Watson, Julie L Gerberding, Kenneth C Frazier, Leslie A Brun, Richard R Deluca, Rita A Karachun, Roger M Perlmutter, Sanat Chattopadhyay, Thomas H Glocer, Weir Mirian M Graddick and Wendell P Weeks. View Insider Buying and Selling for Merck & Co., Inc..

Which major investors are buying Merck & Co., Inc. stock?

MRK stock was purchased by a variety of institutional investors in the last quarter, including Oregon Public Employees Retirement Fund, Norges Bank, Jennison Associates LLC, BlackRock Inc., Geode Capital Management LLC, FMR LLC, APG Asset Management N.V. and Amundi Pioneer Asset Management Inc.. View Insider Buying and Selling for Merck & Co., Inc..

How do I buy shares of Merck & Co., Inc.?

Shares of MRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Merck & Co., Inc.'s stock price today?

One share of MRK stock can currently be purchased for approximately $82.29.

How big of a company is Merck & Co., Inc.?

Merck & Co., Inc. has a market capitalization of $221.87 billion and generates $42.29 billion in revenue each year. The company earns $6.22 billion in net income (profit) each year or $4.34 on an earnings per share basis. Merck & Co., Inc. employs 69,000 workers across the globe.

What is Merck & Co., Inc.'s official website?

The official website for Merck & Co., Inc. is http://www.merck.com.

How can I contact Merck & Co., Inc.?

Merck & Co., Inc.'s mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The company can be reached via phone at 908-740-4000 or via email at [email protected]


MarketBeat Community Rating for Merck & Co., Inc. (NYSE MRK)

Community Ranking:  2.5 out of 5 (star star)
Outperform Votes:  711 (Thanks for Voting!)
Underperform Votes:  739 (Thanks for Voting!)
Total Votes:  1,450
MarketBeat's community ratings are surveys of what our community members think about Merck & Co., Inc. and other stocks. Vote "Outperform" if you believe MRK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/23/2019 by MarketBeat.com Staff

Featured Article: Straddles

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel